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Background: The optimal form of exercise for individuals with cancer has yet to be identified, but there is
evidence that exercise improves their quality of life. The aim of this study is to assess the efficacy and efficiency of
an innovative physical exercise programme, for individuals undergoing chemotherapy for breast, gastrointestinal or
non-small cell lung tumours, for improving quality of life, reducing level of fatigue, and enhancing functional
capacity over time.
Design/Methods: We will conduct a clinical trial in 66 patients with stage IV breast, gastrointestinal or non-small
cell lung cancer, recruited by the Department of Oncology of the referral hospital from 4 primary care health
centres of the Basque Health Service (Osakidetza). These patients will be randomised to one of two groups. The treatment
common to both groups will be the usual care for cancer: optimized usual drug therapies and strengthening of
self-care; in addition, patients in the intervention group will participate in a 2-month exercise programme, including
both aerobic and strength exercises, supervised by nurses in their health centre. The principal outcome variable is
health-related quality of life, measured blindly with the 30-item European Organization for the Research and Treatment
of Cancer Core Quality of Life Questionnaire and Short Form-36 four times: at baseline, and 2, 6 and 12 months later.
The secondary outcome variables are fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire),
functional capacity (6-Minute Walk Test and cardiorespiratory test), muscle strength (hand-held dynamometry and
sit-to-stand test), radiological response to treatment (Response Evaluation Criteria In Solid Tumors) and progression-free
and overall survival. Age, sex, diagnosis, chemotherapy regimen, Eastern Cooperative Oncology Group performance
status and smoking status will be considered as predictive variables. Data will be analysed on an intention-to-treat basis,
comparing changes at each time point between groups, adjusting for baseline values by analysis of covariance.
Discussion: As well as achieving the objectives set, this study will provide us with information on patient perception of
the care received and an opportunity to develop a project based on collaborative action between the primary care and
oncology professionals.
Trial registration: ClinicalTrials.gov Identifier: NCT01786122 Registration date: 02/05/2013.
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Cancer is the second most common cause of death in
industrialised countries [1]. In the coming decades, it is
expected to become the first cause of morbidity and
mortality across the world and it already is in the Basque
Country. In 2008, there were 12.7 million new cases of
cancer worldwide, the most common type being lung
cancer, followed by breast and colorectal cancers. It is
estimated that the worldwide incidence of cancer will
reach 21 million new cases by 2030 [2,3].
At the same time, great advances in the survival of
cancer patients highlight the need to keep their quality
of life as high as possible [4]. Hence, though for many
years survival has been the most important factor in
treatment selection, increasing importance is given to
patient quality of life and complementary therapies are
used to combine the promotion of physical wellness with
meeting holistic and psychosocial needs [5-7]. Physical
exercise has become the cornerstone of this approach in
many diseases [8], and it is plausible that it may help
mitigate some of the adverse effects of treatments in
cancer: decreasing fatigue, increasing cardiorespiratory
fitness and physical condition, and strengthening the im-
mune system, and together with these, reducing recur-
rence rates, extending survival and improving quality of
life [4,5,8-12]. Nevertheless, researchers have only re-
cently started to study its effect in cancer patients [9].
The physical and psychosocial functioning of cancer
patients is impaired by the disease itself and the toxicity
of treatments [13], and in parallel their quality of life de-
teriorates [14,15]. They become increasingly easily fa-
tigued, loose muscle mass and have generalised muscle
weakness as well as lower exercise tolerance [13,16].
Consequently, patients enter a vicious circle of progres-
sively increasing fatigue, dyspnoea and declining func-
tional capacity to perform activities of daily living [17,18].
On the basis of research to date, we can hypothesise
that physical exercise has a positive effect on quality of
life, improves physical condition and reduces fatigue in
cancer patients [11,19-23]. However, the scientific evi-
dence available is still limited, few studies having been
conducted and participants in these studies not being
representative of all cancer patients. The studies have
been small, sometimes without suitable control groups
and, to date, have focused on the survival phase, in
which palliative care is the main priority, rather than the
treatment phase. Nevertheless, some studies have found
that patients who exercise during the treatment phase
improve their functional capacity and experience less
emotional distress and fatigue [24-28]. On the other
hand, it is not yet clear what would be the optimal struc-
ture for an exercise programme, in terms of type, dur-
ation, frequency and intensity, to improve quality of life
in cancer patients [29-33]. It seems that the combinationof aerobic exercise and strength training improves
muscle function, reduces fatigue and improves quality of
life during treatment [34-36]. Nevertheless, more studies
are required to demonstrate that cardiovascular training
combined with strength training is beneficial for patients
diagnosed with cancer at all stages of the disease.Aim
To assess the efficacy and efficiency of an innovative
physical exercise programme, for people under chemo-
therapy for cancer (breast, gastrointestinal and non-
small cell lung cancers), for improving quality of life, re-
ducing level of fatigue, and enhancing functional cap-
acity, compared to usual care alone.Primary objectives
- To measure changes in health-related quality of life
(HRQOL) between baseline and 2 months in interven-
tion and control groups, assessing the difference in
HRQOL between the groups, which is attributable to
exercise.Secondary objectives
- To measure changes in functional capacity and level of
fatigue in the intervention and control groups, assessing
differences between the groups, which are attributable to
exercise.
- To explore whether effects attributable to the interven-
tion vary between subgroups of participants as a function
of age, sex, cancer stage, histological findings, radiotherapy
or chemotherapy regimens, as well as whether any of these
variables play a role as confounders.
- To investigate whether any differences observed at
2 months are maintained in the longer term, in particu-
lar, at 6 and 12 months.Methods/design
Study design
This is a parallel-group randomised controlled clinical
trial in patients with breast, gastrointestinal or non-
small cell lung cancer at stage IV of the disease. The
treatment common to both groups will be the usual care
for cancer, namely, optimized usual drug therapies and
strengthening of self-care. The intervention group will
also receive an intervention based on a supervised exer-
cise programme led by nurses combined with education
on healthy living. The patients included in the study will
pass through two successive phases: a “treatment
optimization phase” and a “phase for follow-up and as-
sessment of results”. Patients are to be followed-up for
1 year, with four blind assessments: at baseline, and 2, 6
and 12 months later (Figure 1).
Potentially eligible patients 
with cancer 




2 months participation in a 
supervised exercise programme 
Control Group 
Usual care 
Follow-up assessments:  
at 2, 6 & 12 months
Figure 1 Study flowchart.
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The Department of Oncology at Cruces University
Hospital will recruit patients from four primary care
health centres of the Basque Health Service (Osakidetza).
Each health centre has a well-established infrastruc-
ture including:
– A laboratory for measuring physical condition with
cycle ergometers, treadmill ergometers, weights,
dumbbells, dynamometers, pulse oximeters,
electrocardiographs, anthropometric measuring
instruments, blood gas analysers, and heart rate
monitors, as well as defibrillators and systems for
data management, among other equipment.
– Shared databases.
– Integrated data management systems based on a private
virtual network connecting all the collaborating centres.
As the centre coordinating the study and provider of
methodological support, the Primary Care Research Unit
has:
– A license for the SAS software to perform all the
statistical analyses.
– Information technology facilities, as well as premises
for carrying out training activities and coordination
meetings.
– Technical secretarial support.
Study population
Inclusion criteria
 Age of 18–70 years old. Histologically confirmed diagnosis of stage IV
breast, gastrointestinal or non-small cell lung cancer
and an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) of 0 or 1.
 Usual first line chemotherapy treatment for the type
of cancer in question.




 High risk of fracture (bone metastasis).
 Decompensated heart disease, uncontrolled
hypertension (systolic blood pressure >200 or
diastolic blood pressure >110 mm Hg), heart failure
(New York Heart Association Class II or greater), or
constrictive pericarditis.
 Other health problems in which physical exercise is
contraindicated, at the discretion of the researchers.
 Regular physical activity (150 min of moderate or
75 min of vigorous physical activity/week).
Recruitment
For recruiting patients, the hospital’s Department of
Oncology will establish a system for identifying patients
discharged with stage IV breast, gastrointestinal or non-
small cell lung cancers. The oncologists will tell patients
about the study, invite them to participate and give them
a written informed consent form, as well as informing
the doctor in charge of the study in the patients’ health
centre. Patients who agree to participate will be included
in the study once they have signed the informed consent
form and baseline data have been collected. They will be
invited to an inclusion visit at which a nurse will carry
out this baseline assessment and record the data.
Randomisation
Randomization will be performed centrally, by phoning
the Primary Care Research Unit, once baseline measure-
ments have been taken at the health centres. Individuals
independent of the organisation responsible for the
study management and researchers will randomize pa-
tients using a computer-based random number gener-
ator. Patients will be registered and allocated on a 1:1
basis to one of the two study arms.
Protocol for the control group
Patients in the control group will all receive the usual
treatment for the type of cancer they have been diag-
nosed with (e.g., platinum-based chemotherapy for non-
small cell lung cancer), following standard oncological
criteria. They will be assessed before, during and after
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protocol.
Protocol for the intervention group
The intervention group treatment differs from that of
the controls in that, in addition to the usual care, they
will participate in a programme based on continuous
and moderate-intensity interval aerobic exercise com-
bined with exercises for muscle strength and joint mo-
bility. The aerobic exercise will be performed on a cycle
ergometer, this system being more suitable than tread-
mill exercise for cancer patients, as adverse effects of
their pharmacological treatment may cause them to have
difficulty with activities requiring balance and coordin-
ation. The exercise programme takes into account the
principles of progression and individualization, as well
precautions regarding exercise by cancer patients.
Phase 1 (8 weeks, 3 sessions/week)
For the first 2 months, patients will follow a progressive
exercise programme consisting of 24 sessions, the inten-
sity being lower at the beginning and increasing in the
second month (Figure 2). Two of the sessions each week
will take place under the supervision of the nurse in the25 35%HHR
Warm up
65 75%HHR
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Figure 2 Exercise programme of the intervention group.laboratory, while the third session is to be carried out
independently in the area around the health centre, with
the aim of promoting patient independence, and for this,
patients are to wear a heart rate monitor pre-
programmed by the nurse. Each laboratory session will
include health education, as well as aerobic exercise and
muscle strength exercises.
Education on healthy living
Patients will receive advice on the type of exercise to do
independently and be taught how to measure their heart
rate and to use the heart rate monitor with heart rate
alerts.
Aerobic exercise
In each session, the intensity of the exercise is adapted
to the physical condition of patient. The activity will be
monitored using the Borg scale to rate the patient’s per-
ceived exertion before and after each session and by
watching for the appearance of symptoms. During the
first month, patients will perform continuous aerobic ex-
ercise at a constant intensity equivalent to 60-70% of
their heart rate reserve (HRR). In the second month, the
intensity of the exercise will be increased, patients2 series of
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minute periods of very high intensity at 75-90% of their
HRR with 2-minute periods of active resting at 40% of
their HRR. This aerobic exercise is to be carried out be-
fore strength exercises to ensure cardiovascular and
muscular warm-up.
Strength and joint mobility exercises
In each session, patients will carry out 8 exercises each
with 2 series of 8–12 repetitions. In this way, the mus-
cles involved in activities of daily living will be exercised
(biceps, triceps, deltoid and trapezius muscles; knee and
hip extensors and flexors; and deep abdominal and back
muscles related to posture), applying a different weight
for each muscle group. Dumbbells and exercise resist-
ance bands will be used for upper limbs and lower limbs,
respectively.
At the end of the supervised exercise, to assess the ac-
ceptance of this type of intervention, the nurse will
interview patients about their experience of the
programme. This interview will be audio recorded and
later analysed by a sociologist experienced in qualitative
analysis.
Phase II
It is envisaged that the training received in Phase I will
help patients to maintain an exercise routine. They will
be trained to carry out an exercise programme similar to




Changes in HRQOL after 2 months to assess the results
of Phase I. HRQOL will be measured blindly using the
30-item European Organization for the Research and
Treatment of Cancer Core Quality of Life Questionnaire
(EORTC QLQ-C30). This questionnaire is specific for
assessing HRQOL of patients with cancer, asking how
they have been feeling in the previous 7 days. The 30
items cover 9 multi-item scales: 5 functional scales
(physical, role, cognitive, emotional and social function-
ing) and 3 symptom scales (fatigue, pain, and nausea/
vomiting), as well as a global health status and quality of
life scale. It also contains ratings of certain symptoms
(dyspnoea, insomnia, appetite loss, constipation and
diarrhoea). The raw scores are linearly transformed to
standard scores between 0 and 100. This questionnaire
has been considered valid and reliable in multiple stud-
ies on cancer patients. In addition, we will use the Short
Form-36 (SF-36) generic quality of life questionnaire.
Both questionnaires have been validated for the Spanish
population [37,38].Secondary outcome measures
 Degree of fatigue measured using the Functional
Assessment of Chronic Illness Therapy-Fatigue
questionnaire (FACIT-Fatigue).
 Radiological response to treatment (Response
Evaluation Criteria In Solid Tumors, RECIST) [39].
 Functional capacity (6-Minute Walk Test;
cardiorespiratory fitness test measured using a cycle
ergometer submaximal exercise test).
 Muscle strength (hand-held dynamometry and
5-times sit-to-stand test).
 Progression-free and overall survival.
Costs The costs will be assessed from the perspective of
the programme. That is, we will only include healthcare
costs related to the intervention, in line with the recom-
mendations of the National Institute for Health and
Clinical Excellence (NICE) in the UK. We will use a
bottom-up approach to estimate costs. This method-
ology consists of recording the resources used by each
centre and converting these into currency units. The
costs will be classified as: 1) time dedicated to the
programme by healthcare staff involved, namely, nurses;
2) consumables; and 3) structural costs.
Predictive (or confounding) variables.
Age, sex, type of cancer (breast, gastrointestinal or
lung), chemotherapy regimen, ECOG PS, and smoking
status.
Adverse events
An external committee will review and compare all non-
serious adverse events, while researchers will be obliged
to report any serious adverse events to the research unit
by fax. A coordination committee with access to all the
information it needs will undertake preliminary analyses
of the data to monitor the safety of the programme. This
committee will be composed of individuals that are inde-
pendent of the organisation responsible for the study
management and members of the research team includ-
ing the study coordinator, all blind to patient allocation.
In addition to serving on the committee, the coordinator
will phone the participating health centres daily, to
check on the progress of the study, report weekly on this
progress to the principal investigator of the study, pro-
duce a monthly report with the study data, and make
recommendations to the study management team.
Follow-up period
One year from the beginning of the intervention.
Sample size
We estimate that we need to analyse 26 patients per
group to detect a difference of 20 points in the global
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cant, a difference considered to be important from the
patient point of view (level of significance, 0.05; power,
0.80 and standard deviation, 25). For this reason, we will
include 33 patients per group, that is, a total of 66,
allowing for a loss to follow-up of 20%. Given that in the
pilot 66% of candidates signed the informed consent
form, we need to invite a total of 100 patients to
participate.
Statistical analysis
The primary outcome variable has been found to have a
normal distribution in previous studies; for variables that
are non-normally distributed, non-parametric tests will
be used and models built suitable for their type of distri-
bution. Analyses will be conducted on an intention-to-
treat basis, and changes between groups compared at
each time point of the follow-up, by analysis of covari-
ance adjusting for baseline levels. The effect attributable
to the intervention will be estimated by assessing the dif-
ferences in improvement in the groups, with 95% confi-
dence intervals. Stratified analysis and statistical models,
linear for continuous outcome variables and logistic for
dichotomous variables (quantitative categorized vari-
ables), will be used to adjust these comparisons for po-
tential confounding factors. To assess the change overall
over the 1-year follow-up, we will estimate the effect of
time on three repeated measures in each subject, using
mixed linear regression models, fixed effect models
(time, intervention, interaction between time and inter-
vention) and random effect models (specific effect of
each subject and each centre on the baseline and on the
effect of time). These models will take into account the
longitudinal nature of the data from three repeated mea-
surements in each patient and will be extended to adjust
for the putative predictive (or confounding) variables.
Estimates will be made of the incremental cost-
effectiveness and cost-utility ratios, dividing the increase in
cost between the groups by the increases in effectiveness
and utility, respectively. Confidence intervals will be calcu-
lated for these ratios using random sampling techniques
(bootstrapping). Sensitivity analysis will be performed,
changing the assumptions of the analysis. All analyses will
be carried out using the SAS statistical package.
Quality control
To ensure the quality of the study data and maximise
the validity and reliability of the programme and meas-
urement of the variables, we will undertake the
following:
 Produce documents for the study: operational
manuals for fieldwork, and forms for registering
measurements and details of the intervention. Store all documentation (informed consent forms,
documents containing results, etc.) in locked
cabinets or on a secure server.
 Provide training for those responsible for the
standardisation of the study process, including
specific training for nurses involved in the study, in
particular, for administration of the quality of life
questionnaires.
 Hold regular meetings.
 Establish a coordinating committee, as noted above,
the coordinator contacting the health centres daily,
requesting the information regarding the study process,
and reporting to the principal investigator weekly.
 Produce progress reports monthly.Ethical and legal aspects
This study protocol complies with the Declaration of
Helsinki and its revisions, as well as with good clinical
practice. The Ethics Committee of the Basque Country
approved the study in the four health centres ensuring it
would be implemented in compliance with the estab-
lished regulations. Regarding data confidentiality, only
the study researchers have access to the data of individ-
uals who agree to participate in the study, in compliance
with the Organic Act 15/1999 of December 13, on the
protection of personal data and its 2011 revision.Limitations
The study will have limited statistical power to detect
changes of less than 10 points on the EORTC QLQ-C30
global scale and subscales, which could still be consid-
ered relevant from the patient point of view. Initially, pa-
tients were going to be recruited from 5 centres, and it
was estimated that a sample of 100 per group would
have been required for detecting this type difference as
significant. However, given that only the coordinating
centre has received funding for this study and a single
centre could not take on the recruitment of that many
patients, we have had to accept a smaller target sample
size and recalculate the statistical power of the sample.
Further, this study does not consider mortality or hos-
pitalisation as primary outcome measures, rather it fo-
cuses on functional capacity and quality of life as the key
factors to attempt to improve in these patients.
The structure of the study means that it is not possible
to adopt a double-blind design (researchers and partici-
pants); however, there will be external assessment that is
independent of the data collection process.
Given that monitoring of the intervention and data
collection are complex, a system for quality control
will be established to ensure standardisation of the
process. Further, in order to avoid the contamination
of the control group, researchers in charge of data
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undertake a pilot study.
Discussion
This study seeks to make an important contribution to
our understanding of the therapeutic effects of exercise in
cancer patients, with the goal of helping them to maintain
a better quality of life. We undertake this work at a time
when clinical interest in the role of physical exercise in
cancer is progressively increasing and in view of the
remaining gaps in our knowledge more than two decades
after the first research studies in this field [40]. It will pro-
vide scientific evidence on the effect of exercise during
chemotherapy, a stage that has been considered in few
studies, in patients with breast gastrointestinal, or non-
small cell lung tumours, most research to date having fo-
cused only on breast or colon cancer.
The study assesses a programme that could be consid-
ered ideal, in the light of current knowledge: it combines
aerobic and strength exercises and is supervised by
nurses to adapt the intensity of the exercise to the
current functional situation of each patient, thereby tak-
ing best advantage of each session while safeguarding
patient safety. At the same time, it empowers patients to
self-manage their own physical training, in accordance
with a self-evaluation of their functional status, their
changing needs over the course of their chemotherapy
and the progress of their tumour. Further, taking a social
and ecological approach including the use of community
resources, the programme encourages ongoing adher-
ence to exercise by patients.
The intervention studied is a single programme for
various different types of cancer that adapts to the re-
quirements of each patient. Previously, specific physical
exercise interventions have been designed for different
types of cancer; however, in an editorial published in the
British Medical Journal in 2011, NH Williams suggested
that this approach should be changed [8]. Multiple re-
cently published research studies and protocols propose
a common intervention for different types of cancer, per-
sonalized to patient needs, which undoubtedly makes
these interventions more cost-effective than those fo-
cused specifically on single types of cancer [22,25,28].
Given that one of the reasons patients refuse to par-
ticipate in exercise programmes is a need to travel [41],
this study is based on “low-tech” facilities, easily access-
ible to patients in their own primary care health centres.
To maintain the effect of exercise in the long term, it is
essential to ensure adherence to the programme.
Regardless of whether the exercise turns out to be ef-
fective, we can be confident that the programme is safe
and does not represent any additional risk for cancer pa-
tients. Specifically, other similar studies have reported
no adverse effects associated with exercise [32,42,43].This study offers the possibility of assessing the experi-
ence of patients with an exercise programme and dem-
onstrates well-coordinated work of the oncology and
primary care units in tertiary prevention. Indeed, given
our positive experience, we are already considering de-
veloping this type of physical exercise programme for in-
dividuals with other chronic disorders.
In summary, our hypothesis is that a programme of
physical exercise coordinated between the oncology and
primary care units, supervised at health centres by
nurses to safeguard patient safety but which can be can
be continued in the community setting, and common
for all types of cancer while tailored to meet individual
patient needs, will be effective in improving the quality
of life of patients with cancer as well as being cost-
effective.
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